Table 1.
Association results for familial PRCA.
| SNP | Position* | Results from Prior GWA† (7) | Case-Control set | MAF | Per allele OR (95% CI) | p-value |
Homogeneity p-value ∥ | |
|---|---|---|---|---|---|---|---|---|
| Controls | Cases | Trend§ | ||||||
| rs2660753 | 3p12 | 1.52 (1.30–1.77) | Set 1 | 0.112 | 0.130 | 1.18 (0.71–1.98) | 0.5196 | |
| 87,193,364 | 1.18 (1.06–1.31) | Set 2 | 0.133 | 0.148 | 1.33 (0.55–2.35) | 0.7729 | ||
| 2.7 × 10−8 | Combined** | 1.17 (0.76–1.80) | 0.4768 | 0.9268 | ||||
| rs9364554 | 6q25 | 1.28 (1.16–1.41) | Set 1 | 0.354 | 0.327 | 0.89 (0.62–1.27) | 0.5227 | |
| 160,753,654 | 1.17 (1.08–1.26) | Set 2 | 0.262 | 0.352 | 1.50 (0.81–2.81) | 0.2019 | ||
| 5.5 × 10−10 | Combined | 1.02 (0.74–1.39) | 0.9214 | 0.1484 | ||||
| rs6465657 | 7q21 | 1.30 (1.19–1.43) | Set 1 | 0.401 | 0.430 | 1.12 (0.81–1.57) | 0.4769 | |
| 97,654,263 | 1.12 (1.19–1.20) | Set 2 | 0.441 | 0.556 | 1.59 (0.87–2.88) | 0.1281 | ||
| 1.1 × 10−9 | Combined | 1.23 (0.92–1.65) | 0.1515 | 0.3184 | ||||
| rs10993994 | 10q11 | 1.62 (1.47–1.78) | Set 1 | 0.347 | 0.457 | 1.59 (1.14–2.22) | 0.0074 | |
| 51,219,502 | 1.25 (1.17–1.34) | Set 2 | 0.434 | 0.444 | 1.04 (0.58–1.88) | 0.8935 | ||
| 8.7 × 10−29 | Combined | 1.42 (1.05–1.90) | 0.0222 | 0.2357 | ||||
| rs7931342 | 11q13 | 0.79 (0.72–0.86) | Set 1 | 0.459 | 0.458 | 0.99 (0.71–1.40) | 0.9785 | |
| 68,751,073 | 0.84 (0.79–0.90) | Set 2 | 0.466 | 0.389 | 0.73 (0.40–1.35) | 0.3078 | ||
| 1.7 × 10−12 | Combined | 0.92 (0.68–1.23) | 0.5709 | 0.3858 | ||||
| rs2735839 | 19q13 | 0.56 (0.50–0.64) | Set 1 | 0.136 | 0.141 | 1.05 (0.65–1.68) | 0.8916 | |
| 56,056,435 | 0.83 (0.75–0.91) | Set 2 | 0.157 | 0.241 | 1.70 (0.83–3.46) | 0.1367 | ||
| 1.5 × 10−18 | Combined | 1.22 (0.81–1.82) | 0.3374 | 0.2634 | ||||
| rs5945619 | Xp11 | 1.46 (1.28–1.66) | Set 1 | 0.370 | 0.453 | 1.41 (0.88–2.27) | 0.1549 | |
| 51,258,412 | 1.19 (1.07–1.31) | Set 2 | 0.353 | 0.519 | 1.98 (0.86–4.57) | 0.1023 | ||
| 1.5 × 10−9 | Combined | 1.54 (1.03–2.31) | 0.0352 | 0.5016 | ||||
*
Chromosome and bp position (build 36);
†
OR (95% CI) for the first and second stage, and the combined p-value as shown in Table 1 of Eeles et al (7);
§
Cochran-Armitage trend test and the Cochran-Mantel-Haenszel meta trend test (except for the X chromosome SNP where an allele test has been performed);
∥
Cochran Q test for homogeneity of the per allele ORs across the two Utah case-control sets;
**
combined total of 169 familial PRCA cases.